Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
- 15 April 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (8) , 1498-1504
- https://doi.org/10.1200/jco.2003.09.114
Abstract
Purpose: To evaluate the antitumor activity, safety, immune response, and replication of CI-1042 (ONYX-015), an E1B 55-kd gene-deleted replication-selective adenovirus, administered intravenously to patients with metastatic colorectal cancerKeywords
This publication has 21 references indexed in Scilit:
- Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trialGene Therapy, 2001
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activityGene Therapy, 2001
- Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trialGene Therapy, 2001
- ONYX-015: Clinical data are encouragingNature Medicine, 1998
- p53-dependent cell death/apoptosis is required for a productive adenovirus infectionNature Medicine, 1998
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996
- The chemotherapy of colon cancer can no longer be ignoredEuropean Journal Of Cancer, 1993
- Dissection of functional domains in the adenovirus 2 early 1b 55k polypeptide by suppressor-linker insertional mutagenesisVirology, 1990
- p53 and DNA polymerase α compete for binding to SV40 T antigenNature, 1987
- Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfectionVirology, 1987